Mixed
Biotin: slow disability worsening in primary progressive MS
primary progressive MS · Mitochondrial / oxidative stress
Controlled trials disagree.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 2
- People in controlled trials
- 786
How the verdict was reached
Mixed phase 3 results
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| MS-SPI | Phase 3 | 144 | 2013 | Met its main goal A total of 13 (12.6%) MD1003-treated patients achieved the primary endpoint versus none of the placebo-treated patients (p = 0.005). Paper abstract | Counted |
| SPI2 | Phase 3 | 642 | 2016 | Missed its main goal For the primary outcome, 39 (12%) of 326 patients in the MD1003 group compared with 29 (9%) of 316 in the placebo group improved at month 12, with confirmation at month 15 (odds ratio 1·35 [95% CI 0·81-2·26]). Paper abstract | Counted |
Counted: 2. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Trials: 1 → 2
- Oct 2026Status changed from Confirmed to Mixed
- Oct 2026Status changed from Results pending to Confirmed
- Oct 2026First listed as Results pending
Related hypotheses
- Acetylcysteine: protect nerve tissue in primary progressive MS
- Metformin: protect nerve tissue in primary progressive MS
- Thioctic acid: protect nerve tissue in primary progressive MS
- Biotin: slow disability worsening in secondary progressive MS
- Metformin: slow disability worsening in primary progressive MS
- Thioctic acid: slow disability worsening in primary progressive MS
- Metformin: reduce relapses and new lesions in primary progressive MS
Assembled by software from public sources.